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A Synchrocyclotron and its Proton Beam
About a year ago Dr T D R Hockaday of the Radcliffe Infirmary approached AERE Harwell on the possibility of emulating the proton therapy work carried out by Dr R N Kjellberg of the Massachusetts General Hospital using the Harvard University synchrocyclotron. Our immediate reaction was that, this should be possible technically as the Harvard and Harwell synchrocyclotrons are almost identical in characteristics and capabilities. Visits to Boston have been made in this intervening period and we are particularly grateful to both Dr Kjellberg and Mr A B Koehler of Harvard University for their generous help and advice. This paper describes some of the characteristics of proton beams and the instrumentation and organization which is being proposed for proton therapy.
Construction of the AERE synchrocyclotron started in 1946. The 700 ton magnet produces a magnetic field of approximately 16 kilogauss (1.6 tesla) and constrains the particles during the acceleration to an energy of 160 MeV. The protons are extracted at this energy in the form of a beam which is then guided to shielded areas where experiments and irradiations are made. The Systematics ofProton Therapy The physical interaction of protons with matter has significant differences from those of neutrons, X-rays, y-rays and electrons and as a result the This behaviour of proton beams arises from two basic processes: (1) A proton traversing matter is continually losing small amounts of its kinetic energy in interactions with atomic electrons; when the whole of the inital kinetic energy has been dispersed in this way the proton is unable to penetrate furtherit has reached the end of its 'range'. In the case of a beam of protons of nominally the same energy, the majority of the protons will come to rest at the same region in the stopping material as shown in Fig 2A. (2) The average energy loss per centimetre or per gram of material traversed by the proton increases as the proton slows down and is largest towards the end of its range. This yields an enhanced dose to the material at the end of the range; this enhancement is termed the 'Bragg peak' (Fig 2B) .
Other phenomena which determine the dose distributions of proton beams are: (1) Straggling: because the energy loss mechanism is statistical, there is a distribution in the end-of-range points of protons in material even if all the incident protons had identically the same kinetic energies (Fig 2c) .
(2) Energy resolution: as the protons in the beam from the synchrocyclotron do not all have identically the same energy this causes a further distribution in the end-of-range points for the protons (Fig 2D) . (3) Scattering: the energy loss mechanism causes protons to be deflected which makes a parallel beam become slightly and increasingly divergent (Fig 2E) . and which involves all these effects. Such small, well-defined dosage volumes are well suited for treating small organs or tumours.
The Bragg peak yielding a high 'target' dose relative to skin dose has been further enhanced by using multiportal treatment techniques (Kjellberg et al. 1972 ) where a number of irradiations are made from different directions so that the skin dose is even further diluted relative to the 'target' dose.
The proton beam intensities required for therapy within the pituitary are well within the capabilities of these accelerators. Beam intensities of less than 0.1 % of the normal proton beams available from these synchrocyclotrons will yield controlled doses of order 10 krad to the pituitary in a few minutes, although the total treatment time per patient is about 90 minutes, mostly taken up with preparation and accurate positioning. Fig 4 shows an impression of the envisaged treatment area designed to reduce patient stress to a minimum. The beam passes through degraders to reduce its energy to the optimum and through collimators to produce a beam having the geometric qualities prescribed by the radiotherapist for the particular patient. The beam then passes through dosimetry devices which measure and monitor the radiation administered to the patient in a manner identical in principle with the systems used for X-ray and y-ray radiotherapy. The patient is shown positioned horizontally with the head located in a stereotaxic frame to allow precise positioning of the pituitary gland in the beam (using two X-ray tubes for this alignment, one of which is pictured above the beam line). The head frame and bed can be rotated through 1800 to administer therapy through a number of portals on both sides of the head. In addition to the provisions for the treatment, due consideration has been given to the patient's comfort preceding and following treatment but these provisions are not described here. Summary This paper has described some physical properties of proton beams and their applicability to therapy. The similarity of the proton beams available from the Harwell and Harvard sychrocyclotrons has been stressed, and some details have been given of a proposal made to the Medical Research Council to use the Harwell synchrocyclotron for proton therapy by emulating the work of the Massachusetts General Hospital and Harvard University and by profiting, from their experience acquired over more than a decade.
In designing this facility we have also taken note of the use (Fowler 1972 ) of proton beam therapy for the treatment of other organs or malignances, as carried out at Harvard, Berkeley, Uppsala and Dubna, and have endeavoured to preserve the possibility of extending into these other areas.
Proposals for the use of proton, pion and heavy ion beams for therapy are becoming very prevalent at this time (Brookhaven National Labora-tory 1972, Los Alamos 1972) and although in this country therapeutic pion and heavy ion beams will not be available for some years the Harwell synchrocyclotron proton beams exist, they are reliable and they can be made available for therapy.
